

EM016025929US



VPI/00-08 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Suzanne Marie Noakes
Group Art Unit : 1656
Applicants : Bhami Shenoy et al.
Application No. : 10/034,950
Confirmation No. : 9344
Filed : December 26, 2001
For : CRYSTALS OF WHOLE ANTIBODIES AND
FRAGMENTS THEREOF AND METHODS FOR
MAKING AND USING THEM

New York, New York
August 27, 2007

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make of record the following documents, copies of which are submitted herewith.*

* For the Examiner's convenience, applicants have also enclosed a completed Form PTO/SB/08A, listing these documents.

OTHER DOCUMENTS

Adams et al., "Generating improved single-chain Fv molecules for tumor targeting," *Journal of Immunological Methods*, 231:249-260 (1999).

Boehm et al., "Crystal structure of the anti-(cacinobryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts," *The Biochemical Journal*, 346(519-528 (2000).

Essig et al., "Crystallization of single-chain Fv proteins," *Journal of Molecular Biology*, 234(3):897-901, (1993).

Matthey, et al., "Recombinant immunotoxins for the treatment of Hodgkin's Disease (review)," *International Journal of Molecular Medicine*, 6(5):509-514 (2000).

REMARKS


Applicants request that the cited documents be (1) fully considered by the Examiner during the course of examination of this application and (2) printed on any patent issuing from this application. Applicants also request that the Examiner initial the enclosed Form PTO/SB/08A in the appropriate places to indicate that the documents have been considered and return a copy of the initialed Form to the undersigned in accordance with MPEP § 609 and § 2001.06(b).

The above documents were cited in a June 1, 2007 Partial European Search Report in a counterpart European application. This communication was received by the undersigned on June 20, 2007 and by our European agents on June 6, 2007. Both dates are within 3 months of the filing of this paper. Applicants have also enclosed a copy of the Partial European Search Report.

Applicants, therefore, believe that no fee is due in connection with this Statement. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Statement to Deposit Account No. 06-1075, Order No. 003662-0018.

The Director is hereby authorized to charge payment of any additional fees required in connection with the accompanying Supplemental Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 06-1075, Order No. 003662-0024.


Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)

Attorneys for Applicants

c/o FISH & NEAVE IP GROUP
ROPES & GRAY LLP
Customer No. 1473
1211 Avenue of the Americas
New York, New York 10036
Tel.: (212) 596-9000
Fax.: (212) 596-9090



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/034,950
		Filing Date	December 26, 2001; Conf. No. 9344
		First Named Inventor	Bhami Shenoy et al.
		Art Unit	1656
		Examiner Name	Suzanne Marie Noakes
Sheet	1	of	1
		Attorney Docket Number	VPI/00-08 US

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published	T ⁴
		Adams et al., "Generating improved single-chain Fv molecules for tumor targeting," <i>Journal of Immunological Methods</i> , 231:249-260 (1999).	
		Boehm et al., "Crystal structure of the anti-(cacinembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts," <i>The Biochemical Journal</i> , 346(519-528 (2000).	
		Essig et al., "Crystallization of single-chain Fv proteins," <i>Journal of Molecular Biology</i> , 234(3):897-901, (1993).	
		Matthey, et al., "Recombinant immunotoxins for the treatment of Hodgkin's Disease (review)," <i>International Journal of Molecular Medicine</i> , 6(5):509-514 (2000).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**